Roblee Allen
Ph.D. Medical Genetics · Sacramento, CANPI 1740264381
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,780 of the $17,926 with a category attached, or 76.9%. United Therapeutics Corporation accounts for 72.9% of it on its own, with 2 other manufacturers making up the rest.
Across 33 payments — averaging $543.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$13K
- Gilead$5K
- CSL Behring$15
Across 73 payments — averaging $5769.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$395K
- Bayer$26K
What the payments were for
- Speaking & faculty fees$13,78077%
- Travel & lodging$2,75715%
- Food & beverage$1,3748%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 20 | $13,065 |
| Gilead | 12 | $4,846 |
| CSL Behring | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few ph.d. medical genetics providers in Californiato place this figure against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.